These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 26631631)

  • 21. Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.
    Park JK; Han A; Czajkowski L; Reed S; Athota R; Bristol T; Rosas LA; Cervantes-Medina A; Taubenberger JK; Memoli MJ
    mBio; 2018 Jan; 9(1):. PubMed ID: 29362240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
    Henry Dunand CJ; Leon PE; Huang M; Choi A; Chromikova V; Ho IY; Tan GS; Cruz J; Hirsh A; Zheng NY; Mullarkey CE; Ennis FA; Terajima M; Treanor JJ; Topham DJ; Subbarao K; Palese P; Krammer F; Wilson PC
    Cell Host Microbe; 2016 Jun; 19(6):800-13. PubMed ID: 27281570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.
    Cho A; Wrammert J
    Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans.
    Christensen SR; Toulmin SA; Griesman T; Lamerato LE; Petrie JG; Martin ET; Monto AS; Hensley SE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An epitope on the stem region of hemagglutinin of H1N1 influenza A virus recognized by neutralizing monoclonal antibody.
    Yan L; Wang H; Sun L; Liu Y; Sun J; Zhao X; Li Y; Xie X; Hu J
    Biochem Biophys Res Commun; 2019 Oct; 518(2):319-324. PubMed ID: 31421820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?
    Neu KE; Henry Dunand CJ; Wilson PC
    Curr Opin Immunol; 2016 Oct; 42():48-55. PubMed ID: 27268395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Hemagglutinin Stem-Reactive Antibodies and Influenza A/H1N1 Virus Infection during the 2009 Pandemic.
    Hoa LNM; Mai LQ; Bryant JE; Thai PQ; Hang NLK; Yen NTT; Duong TN; Thoang DD; Horby P; Werheim HFL; Fox A
    J Virol; 2016 Jul; 90(14):6549-6556. PubMed ID: 27170747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
    Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
    Front Immunol; 2019; 10():756. PubMed ID: 31105689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
    Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Park JK; Xiao Y; Ramuta MD; Rosas LA; Fong S; Matthews AM; Freeman AD; Gouzoulis MA; Batchenkova NA; Yang X; Scherler K; Qi L; Reed S; Athota R; Czajkowski L; Han A; Morens DM; Walters KA; Memoli MJ; Kash JC; Taubenberger JK
    Nat Med; 2020 Aug; 26(8):1240-1246. PubMed ID: 32601336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.
    Nagashima K; Dzimianski JV; Han J; Abbadi N; Gingerich AD; Royer F; O'Rourke S; Sautto GA; Ross TM; Ward AB; DuBois RM; Mousa JJ
    J Immunol; 2022 Jul; 209(1):5-15. PubMed ID: 35697384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
    Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
    J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human monoclonal antibodies neutralizing influenza virus A/H1N1pdm09 and seasonal A/H1N1 strains - Distinct Ig gene repertoires with a similar action mechanism.
    Hiroi S; Kuhara M; Kishi Y; Ono KI; Matsuzawa S; Yamamoto N; Komano J
    Immunobiology; 2018 Mar; 223(3):319-326. PubMed ID: 29107382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.
    Mullarkey CE; Bailey MJ; Golubeva DA; Tan GS; Nachbagauer R; He W; Novakowski KE; Bowdish DM; Miller MS; Palese P
    mBio; 2016 Oct; 7(5):. PubMed ID: 27703076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biogenesis of influenza a virus hemagglutinin cross-protective stem epitopes.
    Magadán JG; Altman MO; Ince WL; Hickman HD; Stevens J; Chevalier A; Baker D; Wilson PC; Ahmed R; Bennink JR; Yewdell JW
    PLoS Pathog; 2014 Jun; 10(6):e1004204. PubMed ID: 24945804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.